期刊文献+

西他列汀关键中间体的合成研究 被引量:2

Research on the Synthesis of Key Intermediate of Sitagliptin
下载PDF
导出
摘要 水合肼(2)经三氟乙酸乙酯和氯乙酰氯取代反应,Vilsmeier试剂关环,得中间体3,再经乙二胺取代,盐酸乙醇关环制得西他列汀关键中间体3-三氟甲基-5,6,7,8-四氢-1,2,4-三唑-[4,3-a]并吡嗪盐酸盐(1),其结构经H NMR和MS确证,总收率达55%。此反应条件温和,同时避免含磷废水产生,更适合工业化生产。 Using hydrazine hydrate(2)as the raw material,compound 3 was obtained through the reaction with ethyl trifluoroacetate,then chloracetylation,cyclization using Vilsmeier reagent.Compound 3 was subjected to ethylendiamine,dehydration and recyclization under hydrochloric acid to obtain the key intermediate of sitagliptin(1)in an overall yield of 55%.The structures of the intermediate and product were characterized by~1H NMR and MS spectra.The advantages of this present process include mild reaction condition and avoiding phosphorus wastewater.Therefore it is promising for industrial application.
作者 陈云华 谭建德 周魏魏 缪炳林 徐龙 周丽萍 CHEN Yun-hua;TAN Jian-de;ZHOU Wei-wei;MIAO Bing-lin;XU Long;ZHOU Li-ping(Chemical Pharmaceutical Research Institute,Taizhou Vocational&Technical College,Taizhou 318000,China;Taizhou Dachen Pharmaceutical Co.,Ltd.,Linhai 317016,China)
出处 《精细化工中间体》 CAS 2022年第3期23-26,共4页 Fine Chemical Intermediates
基金 台州市科技计划项目(21gyb24) 浙江省教育厅高等学校访问工程师校企合作项目(FG2020223)。
关键词 西他列汀 关键中间体 脱水 合成 Sitagliptin key intermediate dehydration synthesis
  • 相关文献

参考文献4

二级参考文献53

  • 1Dreher SD, Ikemoto N, Njolito E, et al. Process to chiral β-amino acid derivatives: WO, 2004085661 [P]. 2004-10-07. (CA 2004, 141: 332476).
  • 2Xiao Y, Armstrong JD, Krska S, et al. Process to chiral amino acid derivatives by asymmetric hydrogenation: WO, 200681151 [P]. 2006-08-03. (CA2006, 145: 189177).
  • 3Biflu T, Feng DD, Liang GB. 3-Amino-4-phenylbutanoic acid derivatives as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes: WO, 2004103276 [P]. 2004-12-02. (CA 2005, 142: 23098).
  • 4Hansen KB, Balsells J, Dreher S, et al. First generation process for the preparation of the DPP-IV inhibitor sitagliptin [J]. Org Process Res Dev, 2005, 9 (5) : 634-639.
  • 5Edmondson SD, Fisher MH, Kim D: Beta-amino heterocyclic dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes: US, 6699871 [P]. 2004-03-02.
  • 6KimD, WangL, BeconiM, etal. (2R)-4-Oxo-4-[3- (trifluoromethyl) -5,6-dihydro [ 1,2,4] triazolo [4,3-a] pyrazin- 7 (8H) -y1] -1- (2,4,5- trifluorophenyl) butan-2-amine: a potent, orally active dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes [J]. J Med Chem, 2005, 48 (11): 141-151. (CA2005, 142: 198023).
  • 7Falchi A, Stivanello M, Serafini S. Process for the preparation of fluorophenylacetic acid and derivatives thereof: WO, 2008078350 [P]. 2008-07-03.
  • 8Perlman N, Etinger M, Niddam-Hildesheim V, et al. Preparation of 3 (R) -amino-4- (2,4,5-trifluorophenyl) butanoic acid esters as intermediates in synthesis of sitagliptin: WO, 2009064476 [P]. 2009-05-22. (CA 2009, 150: 515454).
  • 9HERMAN GA,BERGMAN A,STEVENS C,et al.Effect of single oral doses of sitagliptin,a dipeptidyl peptidase-4 inhibitor,on incretin and plasma glucose levels after an oral glucose tolerance test in patients with type 2 diabetes[J].J Clin Endocrinol Metab,2006,91 (11):4612-4619.
  • 10BERGMAN AJ,STEVENS C,ZHOU Y,et al.Pharmacokinetic and pharmacodynamic properties of multiple oral doses of sitagliptin,a dipeptidyl peptidase-Ⅳ inhibitor:a double-blind,randomized,placebo-controlled study in healthy male volunteers[J].Clin Ther,2006,28(1):55 -72.

共引文献78

同被引文献16

引证文献2

二级引证文献2

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部